Literature DB >> 20508291

Selenitetriglicerydes affect CYP1A1 and QR activity by involvement of reactive oxygen species and Nrf2 transcription factor.

Piotr Suchocki1, Irena Misiewicz-Krzemińska, Katarzyna Skupińska, Katarzyna Niedźwiecka, Katarzyna Lubelska, Zbigniew Fijałek, Teresa Kasprzycka-Guttman.   

Abstract

Selenitetriglycerides are a group of compounds that contain selenium (Se) (IV). In this paper, we present the results of examinations of three structurally-related selenitetriglicerydes that contain various Se concentrations: 2%, 5% and 7% Selol. The present study concentrates on the effect of Selol on phase 1 and 2 enzyme activity and the implications of free radicals and the nuclear erythroid 2-related factor 2 (Nrf2)-antioxidant response element (ARE) pathway in the activity of this compound. The cytotoxic and cytostatic activities of the three kinds of Selol were evaluated; however, the cytotoxic effect was observed only for 7% Selol. Our results show that 2% Selol acts as a monofunctional inducer of phase 2 enzyme activity, and the induction is mediated by the Nrf2 transcription factor. Selol 7% acts in an opposite manner and induces phase 1 with simultaneous inhibition of phase 2 enzyme activity. The differential effect can be associated with the increase in Se content, leading to a change in the structure of the compound.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20508291     DOI: 10.1016/s1734-1140(10)70275-9

Source DB:  PubMed          Journal:  Pharmacol Rep        ISSN: 1734-1140            Impact factor:   3.024


  7 in total

1.  PVM/MA-shelled selol nanocapsules promote cell cycle arrest in A549 lung adenocarcinoma cells.

Authors:  Ludmilla Regina de Souza; Luis Alexandre Muehlmann; Mayara Simonelly Costa Dos Santos; Rayane Ganassin; Rosana Simón-Vázquez; Graziella Anselmo Joanitti; Ewa Mosiniewicz-Szablewska; Piotr Suchocki; Paulo César Morais; África González-Fernández; Ricardo Bentes Azevedo; Sônia Nair Báo
Journal:  J Nanobiotechnology       Date:  2014-08-23       Impact factor: 10.435

2.  Preliminary study on Se-enriched Lentinula edodes mycelium as a proposal of new feed additive in selenium deficiency.

Authors:  Bożena Muszyńska; Ewelina Szacawa; Dorota Bederska-Łojewska; Katarzyna Dudek; Bartosz Pomierny; Anna Włodarczyk; Katarzyna Kała; Jan Lazur; Piotr Suchocki; Bogusława Budziszewska; Dariusz Bednarek; Marek Pieszka
Journal:  PLoS One       Date:  2020-05-21       Impact factor: 3.240

Review 3.  Selenium Compounds as Novel Potential Anticancer Agents.

Authors:  Dominika Radomska; Robert Czarnomysy; Dominik Radomski; Krzysztof Bielawski
Journal:  Int J Mol Sci       Date:  2021-01-20       Impact factor: 6.208

Review 4.  Therapeutic Benefits of Selenium in Hematological Malignancies.

Authors:  Melanie A Ehudin; Upendarrao Golla; Devnah Trivedi; Shobha D Potlakayala; Sairam V Rudrabhatla; Dhimant Desai; Sinisa Dovat; David Claxton; Arati Sharma
Journal:  Int J Mol Sci       Date:  2022-07-19       Impact factor: 6.208

5.  Effect of Supplementation with the Combination of Se-Enriched Lentinula edodes Mycelium, Exogenous Enzymes, Acidifiers, Sodium Butyrate and Silicon Dioxide Nanoparticle Feed Additives on Selected Parameters in Calves.

Authors:  Ewelina Szacawa; Katarzyna Dudek; Magdalena Wasiak; Dariusz Bednarek; Dorota Bederska-Łojewska; Bożena Muszyńska; Marek Pieszka
Journal:  Molecules       Date:  2022-08-13       Impact factor: 4.927

6.  Comparison of selected gene expression profiles in sensitive and resistant cancer cells treated with doxorubicin and Selol.

Authors:  Jadwiga Dudkiewicz-Wilczyńska; Agnieszka Grabowska; Iza Książek; Karolina Sitarz; Piotr Suchocki; Elżbieta Anuszewska
Journal:  Contemp Oncol (Pozn)       Date:  2014-06-03

7.  The Comparison of MTT and CVS Assays for the Assessment of Anticancer Agent Interactions.

Authors:  Lidia Śliwka; Katarzyna Wiktorska; Piotr Suchocki; Małgorzata Milczarek; Szymon Mielczarek; Katarzyna Lubelska; Tomasz Cierpiał; Piotr Łyżwa; Piotr Kiełbasiński; Anna Jaromin; Anna Flis; Zdzisław Chilmonczyk
Journal:  PLoS One       Date:  2016-05-19       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.